Details for New Drug Application (NDA): 206038

NDA 206038 describes ORKAMBI, which is a drug marketed by Vertex Pharms Inc and is included in two NDAs. It is available from one supplier. There are twenty-one patents protecting this drug. Additional details are available on the ORKAMBI profile page.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; lumacaftor profile page.

Summary for 206038

Tradename:	ORKAMBI
Applicant:	Vertex Pharms Inc
Ingredient:	ivacaftor; lumacaftor
Patents:	21

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206038

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 206038

Mechanism of Action

Chloride Channel Activation Potentiators Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 2C9 Inducers Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors P-Glycoprotein Inducers P-Glycoprotein Inhibitors

Suppliers and Packaging for NDA: 206038

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038	NDA	Vertex Pharmaceuticals Incorporated	51167-700	51167-700-02	4 CARTON in 1 BOX (51167-700-02) / 7 BLISTER PACK in 1 CARTON / 4 TABLET, FILM COATED in 1 BLISTER PACK
ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038	NDA	Vertex Pharmaceuticals Incorporated	51167-809	51167-809-01	4 CARTON in 1 BOX (51167-809-01) / 7 BLISTER PACK in 1 CARTON / 4 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	125MG;200MG
Approval Date:	Jul 2, 2015	TE:		RLD:	Yes
Patent:		Patent Expiration:	Dec 4, 2028	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR
Patent:		Patent Expiration:	Dec 4, 2028	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
Patent:		Patent Expiration:	Aug 13, 2029	Product Flag?	Y	Substance Flag?		Delist Request?

Complete Access Available with Subscription